Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014, WKN: 905249

Market price date: 04.06.2021
Market price: 5,35 USD




Cerus Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2021
Cash flow
Net operating cash flow -40.743.000
Capital Expenditures -1.615.000
Free cash flow -42.358.000
Balance sheet
Total Equity 103.806.000
Liabilities & Shareholders equity 221.415.000
Income statement
Net income -59.857.000
Eps (diluted) -0,370
Diluted shares outstanding 168.170.000
Net sales/revenue 114.249.000

Fundamental ratios calculated on: 04-06-2021

Ratios
Key figures 04-06-2021
Cash flow
P/C -23,20
   
P/FC -21,24
Balance sheet
ROI-27,03
ROE46,88
Income statement
P/E-14,46
Div. Yield0,00%
P/B9,11
P/S7,88


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCERS
Market Capitalization945.115.392,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.cerus.com


Description of the company

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company´s technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received Conformite Europeene (CE) marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, the Middle East and selected countries in other regions worldwide. The Company sells both the platelet and plasma systems using its direct sales force and through distributors.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.cerus.com